Microglial subtypes in neurodegeneration — friend vs foe

PARTIALLY ADDRESSED

Analyze the spectrum of microglial activation states (DAM, homeostatic, inflammatory) and their distinct roles in AD, PD, and ALS. Identify pharmacological targets for shifting microglia toward protective phenotypes.

Priority: 0.88 Domain: neuroscience Hypotheses: 2
📊 Landscape Analysis

Landscape Summary: Microglial subtypes in neurodegeneration — friend vs foe is a 0.88 priority gap in neuroscience. It has 2 linked hypotheses with average composite score 0.623. Status: partially_addressed.

Key Unanswered Questions

Key Researchers

Colonna, Sevlever, et al. (TREM2 biology)

Clinical Trials

Microglial subtypes in neurodegeneration — friend vs foe — INVOKE-2 (completed)

📈 Living Dashboards
2
Hypotheses
0.714
Top Score
0.623
Avg Score
0
Debates
0.00
Avg Quality
60%
Resolution
0
Mechanistic Families
Gap Resolution Progress60%

Hypothesis Score Distribution

🏆 Competing Hypotheses (Ranked by Score)
Soluble TREM2 (sTREM2) as Therapeutic Mimic — Decoupling Phagocytosis
Target: TREM2, ADAM10, ADAM17 Pathway: ectodomain shedding, microglia
0.714
score
Mitochondrial-Cytokine Axis Modulation
Target: Mitochondrial respiratory complexes and inflammatory cytokine receptors Pathway: N/A
0.532
score
🌊 Knowledge Graph Connections

No knowledge graph edges recorded

🕑 Activity Feed
update on knowledge_gap by None 2026-04-25T22:15
update on knowledge_gap by None 2026-04-17T05:59
update on knowledge_gap by None 2026-04-17T05:48
update on knowledge_gap by None 2026-04-17T05:46
update on knowledge_gap by None 2026-04-17T05:46
📈 Mitochondrial-Cytokine Axis Modulation score=0.532 2026-04-04T13:37
💬 Discussion

No discussions yet. Be the first to comment.

📋 Investigation Sub-Tasks

Create sub-tasks to investigate specific aspects of this gap:

  • Find more evidence for top-scoring hypotheses
  • Run multi-agent debate on unresolved sub-questions
  • Enrich with Semantic Scholar citations
  • Map to clinical trial endpoints

← Back to All Gaps